Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy

dc.contributor.authorInal, M
dc.contributor.authorKanbak, G
dc.contributor.authorSen, S
dc.contributor.authorAkyüz, F
dc.contributor.authorSunal, E
dc.date.accessioned2024-06-12T11:03:06Z
dc.date.available2024-06-12T11:03:06Z
dc.date.issued1999
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIn this study, plasma and red blood cell (RBC) antioxidant status and plasma lipid peroxidation were investigated in 46 hemodialysis patients. In addition, the effect of erythropoietin (EPO) and EPO-vitamin E combination therapy on plasma and RBC antioxidant status, and plasma lipid peroxidation were examined. There were 10 healthy subjects in the control group and 10 hemodialysis patients in the untreated group. The third group included 36 hemodialysis patients that were given EPO (100 U/kg) for 3 months, 3 times per week. The fourth group included 36 hemodialysis-patients from the EPO group that were given EPO at a 50% decreased dose + vitamin E (300 mg/day) for 3 months. MDA levels in the untreated group, the EPO group and the EPO + vitamin E groups were found to be higher than the control group (p < 0.001, in both). Furthermore, MDA levels in both of the treatment groups were lower when compared to the untreated group (p < 0.001, in both). Plasma vitamin E levels in the untreated, the EPO group and EPO + vitamin E groups were lower than the control group (p < 0.001). In contrast, plasma vitamin E levels in the treatment groups were higher in comparison with the control group (p < 0.05). SOD activities in the untreated, the EPO group and the EPO + vitamin E groups were found to be lower than the control group (p < 0.001). SOD activities in the treatment groups were higher than the control group (p < 0.001). The SOD activities in the EPO + vitamin E group increased when compared to the EPO group (p < 0.001). CAT activities in the untreated, the EPO group and the EPO + vitamin E groups were found to be lower than the control group (p < 0.001 in untreated and EPO groups, p < 0.01 in EPO + vitamin E group). CAT activities in EPO and EPO + vitamin E groups were increased when compared to the untreated group (p < 0.01). In conclusion, our findings have shown that antioxidant status decreased and lipid peroxidation increased in hemodialysis patients. EPO has an antioxidant effect on the RBC and plasma antioxidant status, and plasma lipid peroxidation. These effects were moderately increased by the combination of vitamin E and EPO.en_US
dc.identifier.doi10.1080/10715769900300771
dc.identifier.endpage216en_US
dc.identifier.issn1071-5762
dc.identifier.issn1029-2470
dc.identifier.issue3en_US
dc.identifier.pmid10499778en_US
dc.identifier.scopus2-s2.0-0032868729en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage211en_US
dc.identifier.urihttps://doi.org/10.1080/10715769900300771
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21531
dc.identifier.volume31en_US
dc.identifier.wosWOS:000082501300007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofFree Radical Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHemodialysisen_US
dc.subjectErythropoietinen_US
dc.subjectVitamin Een_US
dc.subjectSuperoxide Dismutaseen_US
dc.subjectCatalaseen_US
dc.subjectMalondialdehydeen_US
dc.subjectSuperoxide-Dismutase Activityen_US
dc.subjectErythrocytesen_US
dc.subjectDialysisen_US
dc.subjectCellsen_US
dc.titleAntioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapyen_US
dc.typeArticleen_US

Dosyalar